-
Je něco špatně v tomto záznamu ?
Účinnost a bezpečnost intravitreálního dexametazonového implantátu u diabetického makulárního edému rezistentního na léčbu: šestiměsíční výsledky
[Efficacy and safety of intravitreal Dexamethasone implant in treatment-resistant diabetic macular edema: Six-month results]
Mustafa Berhuni, İbrahim Edhem Yılmaz, Gürbostan Gizem Soysal, Özcan Zeynep Özer, Doğan Levent
Jazyk čeština Země Česko
PubMed
39891556
DOI
10.31348/2025/4
Meditorial
- MeSH
- dexamethason * aplikace a dávkování škodlivé účinky MeSH
- diabetická retinopatie farmakoterapie komplikace MeSH
- glukokortikoidy aplikace a dávkování MeSH
- injekce intravitreální MeSH
- lidé MeSH
- makulární edém * etiologie farmakoterapie MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
Aims: To investigate the efficacy and safety of intravitreal Dexamethasone implant (DEX-I) therapy in the treatment of diabetic macular edema (DME) refractory to intravitreal bevacizumab (IVB). Material and methods: This retrospective and cross-sectional study included 37 eyes of 37 patients who received 3 loading doses of IVB injections for DME with no response and underwent DEX-I implant. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) measurements and central foveal thickness (CFT) measured by spectral domain optical coherence tomography (SD-OCT) were recorded and compared before DEX-I, at the first week, first, second, third and sixth months. Duration of DME, glycated hemoglobin (HbA1c) levels, DME types and lens status (phakic, pseudophakic) were also recorded. Results: The mean age of the patients was 61.14 ±8.69 years (59.5% male, 40.5% female). 35.1% of the patients had cystoid macular edema, 64.9% had diffuse macular edema and 73 % were phakic and 27% were pseudophakic. BCVA, CFT and IOP values before DEX-I injection were 0.78 ±0.16 LogMAR, 493.73 ±107.6 μm and 13.05 ±2.59 mmHg, respectively. At 6 months after DEX-I, BCVA, CFT and IOP values were 0.64 ±0.11 LogMAR, 397.35 ±59.72 μm and 16.3 ±2.51 mmHg, respectively. In all follow-ups, there was a significant improvement in BCVA, a significant decrease in CFT and a significant increase in IOP compared to pre-injection. Ocular hypertension was observed in 0.8 % of patients and progression of cataract progression in 1% of patients after treatment. Conclusion: DEX-I therapy is an effective and safe treatment option for DME refractory to IVB treatment.
Gaziantep City Hospital Gaziantep Turkey
Niğde Ömer Halisdemir University Medical Faculity Department of Ophthalmology Niğde Turkey
Efficacy and safety of intravitreal Dexamethasone implant in treatment-resistant diabetic macular edema: Six-month results
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25013622
- 003
- CZ-PrNML
- 005
- 20251010094245.0
- 007
- ta
- 008
- 250828s2025 xr cd f 000 0|cze||
- 009
- AR
- 024 7_
- $a 10.31348/2025/4 $2 doi
- 035 __
- $a (PubMed)39891556
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Berhuni, Mustafa $u Gaziantep Islam, Science and Technology University, Medical Faculity, Department of Ophthalmology, Gaziantep, Turkey
- 245 10
- $a Účinnost a bezpečnost intravitreálního dexametazonového implantátu u diabetického makulárního edému rezistentního na léčbu: šestiměsíční výsledky / $c Mustafa Berhuni, İbrahim Edhem Yılmaz, Gürbostan Gizem Soysal, Özcan Zeynep Özer, Doğan Levent
- 246 31
- $a Efficacy and safety of intravitreal Dexamethasone implant in treatment-resistant diabetic macular edema: Six-month results
- 520 9_
- $a Aims: To investigate the efficacy and safety of intravitreal Dexamethasone implant (DEX-I) therapy in the treatment of diabetic macular edema (DME) refractory to intravitreal bevacizumab (IVB). Material and methods: This retrospective and cross-sectional study included 37 eyes of 37 patients who received 3 loading doses of IVB injections for DME with no response and underwent DEX-I implant. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) measurements and central foveal thickness (CFT) measured by spectral domain optical coherence tomography (SD-OCT) were recorded and compared before DEX-I, at the first week, first, second, third and sixth months. Duration of DME, glycated hemoglobin (HbA1c) levels, DME types and lens status (phakic, pseudophakic) were also recorded. Results: The mean age of the patients was 61.14 ±8.69 years (59.5% male, 40.5% female). 35.1% of the patients had cystoid macular edema, 64.9% had diffuse macular edema and 73 % were phakic and 27% were pseudophakic. BCVA, CFT and IOP values before DEX-I injection were 0.78 ±0.16 LogMAR, 493.73 ±107.6 μm and 13.05 ±2.59 mmHg, respectively. At 6 months after DEX-I, BCVA, CFT and IOP values were 0.64 ±0.11 LogMAR, 397.35 ±59.72 μm and 16.3 ±2.51 mmHg, respectively. In all follow-ups, there was a significant improvement in BCVA, a significant decrease in CFT and a significant increase in IOP compared to pre-injection. Ocular hypertension was observed in 0.8 % of patients and progression of cataract progression in 1% of patients after treatment. Conclusion: DEX-I therapy is an effective and safe treatment option for DME refractory to IVB treatment.
- 650 07
- $a lidé $7 D006801 $2 czmesh
- 650 17
- $a dexamethason $x aplikace a dávkování $x škodlivé účinky $7 D003907 $2 czmesh
- 650 07
- $a diabetická retinopatie $x farmakoterapie $x komplikace $7 D003930 $2 czmesh
- 650 07
- $a glukokortikoidy $x aplikace a dávkování $7 D005938 $2 czmesh
- 650 07
- $a injekce intravitreální $7 D058449 $2 czmesh
- 650 17
- $a makulární edém $x etiologie $x farmakoterapie $7 D008269 $2 czmesh
- 650 07
- $a retrospektivní studie $7 D012189 $2 czmesh
- 700 1_
- $a Yılmaz, İbrahim Edhem $u Gaziantep Islam, Science and Technology University, Medical Faculity, Department of Ophthalmology, Gaziantep, Turkey
- 700 1_
- $a Soysal, Gizem Gürbostan $u Gaziantep City Hospital, Gaziantep, Turkey
- 700 1_
- $a Özcan, Zeynep Özer $u Gaziantep City Hospital, Gaziantep, Turkey
- 700 1_
- $a Doğan, Levent $u Niğde Ömer Halisdemir University, Medical Faculity, Department of, Ophthalmology, Niğde, Turkey
- 773 0_
- $w MED00010980 $t Česká a slovenská oftalmologie $x 1211-9059 $g Roč. 81, č. 3 (2025), s. 151-156
- 856 41
- $u https://www.prolekare.cz/casopisy/ceska-slovenska-oftalmologie/2025-3-2/efficacy-and-safety-of-intravitreal-dexamethasone-implant-in-treatment-resistant-diabetic-macular-edema-six-month-results-139703 $y Meditorial
- 910 __
- $a ABA008 $b A 202 $c 639 $y p $z 0
- 990 __
- $a 20250619 $b ABA008
- 991 __
- $a 20251010094231 $b ABA008
- 999 __
- $a ok $b bmc $g 2392139 $s 1250740
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2025 $b 81 $c 3 $d 151-156 $i 1211-9059 $m Česká a slovenská oftalmologie $x MED00010980 $y 139703
- LZP __
- $c NLK109 $d 20251002 $b NLK111 $a Meditorial-20250619
